Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin

Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin

BackgroundEltrombopag has demonstrated efficacy in treating low platelet (PLT) levels, but it remains unclear whether eltrombopag can promote PLT engraftment after hematopoietic stem cell transplantation (HSCT).MethodsForty-one HSCT patients received eltrombopag 50 mg/d from +1 day until PLT &gt...

Full description

Bibliographic Details
Main Authors:	Yahan Li, Fansheng Kong, Guanchen Bai, Yujie Jiang, Wenlu Zhang, Xue Sun, Xiaohui Sui, Ying Li, Mei Ding, Dai Yuan, Xin Wang, Xiaosheng Fang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-04-01
Series:	Frontiers in Immunology
Subjects:	eltrombopag thrombopoietin safety prognosis allogeneic hematopoietic stem cell transplantation platelet engraftment
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1340908/full

Similar Items

The Efficacy of Eltrombopag Treatment in Patients who developed Platelet Engraftment Failure after Allogeneic Stem Cell Transplantation: A Single Center Experience
by: Ali ESER, et al.
Published: (2021-03-01)

Thrombopoietin enhances hematopoietic stem and progenitor cell homing by impeding matrix metalloproteinase 9 expression
by: Yiming Liu, et al.
Published: (2020-06-01)

Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag
by: Cen Tang, et al.
Published: (2018-08-01)

Review article: THE ROLE OF ELTROMBOPAG AND ROMIPLOSTIM AS THE THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) IN TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): WHAT IS TPO-RA, WHEN TPO-RA IS USED AND HOW TO TAKE TPO-RA?
by: Jefri Pratama Susanto
Published: (2016-11-01)

A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia
by: Qiuhua Zhu, et al.
Published: (2021-08-01)

Efficacy of Eltrombopag in Children with Post-Stem Cell Transplant Prolonged Isolated Thrombocytopenia
by: Megumi Matsumoto, et al.
Published: (2022-08-01)

The Use of High Dose Eltrombopag in the Management of Sepsis-Associated Thrombocytopenia in Critically Ill Patients
by: Hasan Md. Jahidul, et al.
Published: (2019-11-01)

Thrombopoietin receptor agonists in pharmacotherapy of pediatric immune thrombocytopenia
by: Olga S. Levchenkova, et al.
Published: (2023-03-01)

Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia
by: Angelica Maria Garzon, et al.
Published: (2015-08-01)

Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience
by: Füsun Özdemirkıran, et al.
Published: (2015-12-01)

Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience
by: Füsun Özdemirkıran, et al.
Published: (2015-11-01)

Use of Eltrombopag in Improving Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation
by: Samip Master, et al.
Published: (2018-03-01)

Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes
by: Sarah Jungius, et al.
Published: (2023-08-01)

Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently
by: Mohamed A. Yassin, et al.
Published: (2023-12-01)

Eltrombopag for Treatment of Thrombocytopenia Following Hematopoietic Stem Cell Transplantation
by: Zeynep Tuğba Güven, et al.
Published: (2022-05-01)

A novel recombinant human thrombopoietin for treating prolonged isolated thrombocytopenia after allogeneic stem cell transplantation
by: Yu-Qian Sun, et al.
Published: (2019-11-01)

Thrombopoietin from hepatocytes promotes hematopoietic stem cell regeneration after myeloablation
by: Longfei Gao, et al.
Published: (2021-08-01)

Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice
by: V V PTUSHKIN, et al.
Published: (2018-07-01)

The role of thrombopoietin receptor agonists in the management of adult primary immune thrombocytopenia: A single centre experience
by: Virijević Marijana, et al.
Published: (2022-01-01)

Evaluation of safety, efficacy and pharmacokinetics of Eltrombopag in patients with chronic immune thrombocytopenia: Meta-analysis of randomized controlled trials Authors
by: Abdullah AL-Dhuraibi, et al.
Published: (2023-06-01)

Long term use of eltrombopag in children with chronic immune thrombocytopenia: extended real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology
by: Paola Giordano, et al.
Published: (2023-07-01)

Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation
by: Maite Alvarez, et al.
Published: (2021-01-01)

Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis
by: Joyce Tumaini Massaro, et al.
Published: (2019-10-01)

Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States
by: Tremblay G, et al.
Published: (2019-11-01)

Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation
by: Leyre Bento, et al.
Published: (2022-03-01)

Off Label Use of Eltrombopag and Recombinant Activated Factor VII in Wiskott-Aldrich Syndrome. A Case Report and Review of Literature
by: Alkistis Adramerina, et al.
Published: (2022-04-01)

Role of thrombopoietin stimulating agents(Eltrombopag and Romiplostim) in immune thrombocytopenia secondary to SLE
by: Toro Vélez, Esteban, et al.
Published: (2021-07-01)

The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN
by: Jerry L. Spivak, et al.
Published: (2021-03-01)

Serum thrombopoietin and cMpl expression in thrombocytopenia of different etiologies
by: Fabrizio Vianello, et al.
Published: (2014-03-01)

The thrombopoietin receptor: revisiting the master regulator of platelet production
by: Ian S. Hitchcock, et al.
Published: (2021-08-01)

Real-world experience of treatment with thrombopoietin receptor agonists in anti-thymocyte globulin-naïve patients with aplastic anemia: an observational retrospective analysis in a single institution
by: Masaki Iino, et al.
Published: (2022-12-01)

Avatrombopag for the treatment of thrombocytopenia in children's patients following allogeneic hematopoietic stem-cell transplantation: A pilot study
by: Yongsheng Ruan, et al.
Published: (2023-02-01)

Renal transplant in a patient with idiopathic thrombocytopenic purpura refractory to steroid and intravenous immunoglobulin
by: Shubham Agarwal, et al.
Published: (2019-01-01)

Successful treatment of acquired amegakaryocytic thrombocytopenia with eltrombopag and immunosuppressant
by: Hong Tian, et al.
Published: (2022-08-01)

Comparison of Splenectomy and Eltrombopag Treatment in the Second-Line Treatment of Immune Thrombocytopenic Purpura
by: Mehmet Can Uğur, et al.
Published: (2021-08-01)

Aplastic anemia with thrombopoietin gene mutation successfully treated with romiplostim monotherapy
by: Niranjan Gurunath Hegde, et al.
Published: (2023-01-01)

CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS
by: E. A. Pyadushkina, et al.
Published: (2016-02-01)

Romiplostim use for thrombocytopenia following allogeneic hematopoietic stem cell transplantation: a case series from a single center in Qatar
by: Abdulrahman F. Al-Mashdali, et al.
Published: (2023-12-01)

CD4+FOXP3+ Regulatory T Cell Therapies in HLA Haploidentical Hematopoietic Transplantation
by: Antonella Mancusi, et al.
Published: (2019-12-01)

Successful Eltrombopag Therapy in a Child with MYH9-Related Inherited Thrombocytopenia
by: Giuseppe Lassandro, et al.
Published: (2022-11-01)